Over the past decades, a multitude of experimental drugs have been shown to delay
disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but …

Amyotrophic lateral sclerosis (ALS) is the commonest form of motor neuron disease and is a
fatal, degenerative, multisystem disorder affecting upper and/or lower motor neurons in the …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease marked by
progressive loss of muscle function. It is the most common adult‐onset form of motor neuron …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, characterized by
progressive motor neuron degeneration, muscle weakness, paralysis, and ultimately death …

Amyotrophic lateral sclerosis (ALS) is a clinically progressive neurodegenerative syndrome
predominantly affecting motor neurons and their associated tracts. Riluzole and edaravone …

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, adult-onset neurodegenerative
disease characterized by selective dysfunction and death of motor neurons in the brain and …

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that is currently
untreatable. Many compounds have been tested in laboratory-based models and in patients …

Owing to uncertainty on the pathogenic mechanisms underlying motor neuron degeneration
in amyotrophic lateral sclerosis (ALS) riluzole remains the only available therapy, with only …

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease associated with
motor neuron degeneration, muscle weakness, paralysis and finally death. The proposed …

The cause of the fatal motor neuron disease, amyotrophic lateral sclerosis (ALS), remains
largely unknown. Most cases of ALS are sporadic and, for~ 20% of familial ALS patients …